Science and Enterprise

Tag: equity

  • Biopharm Raises $45.9M in Venture Funding for Ear Disorders

    Otonomy Inc., a biopharmaceutical company in San Diego specializing in middle and inner-ear disorders, collected $45.9 million in its third venture financing round. OrbiMed Advisors, a venture capital company specializing in health care investments, led the round with new investors Aperture Venture Partners and Osage University Partners taking part, along with current investors Avalon Ventures,…

  • Medtronic Acquires Telemedicine Systems Developer

    Medtronic Inc., a medical device company in Minneapolis, Minnesota, is buying Cardiocom, a developer of telemedicine systems in nearby Chanhassen, Minnesota, in an all-cash transaction valued at $200 million. Medtronic’s devices currently help treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal disorders. Cardiocom, founded in 1999 and privately held, builds solutions for home…

  • GSK Starts Venture Fund for Nerve-Signal Devices, Medicines

    The pharmaceutical company GlaxoSmithKline is starting a venture capital fund to invest in companies making therapeutic devices and medications harnessing the body’s electrical signaling system. The fund, called Action Potential Venture Capital (APVC) Ltd. will have $50 million, with its first investment in a California company developing a device to regulate nerve signals for treating…

  • Genomics Therapy Company Secures $60M Venture Financing

    Dicerna Pharmaceuticals Inc., in Watertown, Massachusetts, closed its third round of venture financing after start-up with $60 million in additional capital from new and current investors. Dicerna is a six year-old biotechnology company developing therapies harnessing genomic material to silence genes causing diseases. Dicerna’s technology is based on ribonucleic acid or RNA interference (RNAi), a…

  • Actelion to Acquire Developer of Rare Cancer Treatment

    Actelion Ltd, a biopharmaceutical company based in Switzerland, acquired Ceptaris Therapeutics Inc., a specialty pharmaceutical developer in Malvern, Pennsylvania, in a deal with a potential value of at least $250 million. The acquisition, however, depends on the U.S. Food and Drug Administration approving Ceptaris’s only current product, a topical treatment for symptoms from a rare…

  • TB Diagnostics Developer Gains $1.5M in Early Financing

    TB Biosciences, a biotechnology company in Bethlehem, Pennsylvania developing genomics-based diagnostics for tuberculosis, received $1.5 million in its first fund-raising round after initial start-up. The financing was led by Bethlehem venture capital company Originate Ventures, joined by Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. Tuberculosis, or TB, is a…

  • Venture Funding Down in 2Q, Health Companies Score in Exits

    Venture capital (VC) funding of start-up companies in the U.S. continued its decline in the second quarter of 2013, but biotechnology start-ups figured prominently in gaining liquidity during that quarter. The data, compiled by the investment industry research service Dow Jones VentureSource, shows U.S. companies raised $7.2 billion in 801 deals during the second quarter, registering declines…

  • Stem Cell Developer-Supplier Issues Initial Public Offering

    Cellular Dynamics International in Madison, Wisconsin, a developer and supplier of human stem cells in bulk quantities, filed an initial public offering (IPO) of its stock with the U.S. Securities and Exchange Commission. The company is issuing some 3.85 million shares, which it expects to price at $12.00 to $14.00 a share, giving it an…

  • Alternative Solar Cell Developer Adds $10M Venture Funding

    Scifiniti, a developer of silicon-based solar materials in San Jose, California secured $10 million in series B venture financing, the second round of funding after initial start-up. Current investors Alloy Ventures, Firelake Capital, I2BF Global Ventures, and Peninsula Ventures took part in the round. The company’s first product is SmartWafer, an alternative photovoltaic solar cell…

  • Celgene, MorphoSys Partner on Multiple Myeloma Antibody

    Celgene Corporation, a biopharmaceutical company in Summit, New Jersey, agreed to license  technology and invest in the biotechnology company MorphoSys AG in Munich, Germany for commercializing a monoclonal antibody developed by MorphoSys to treat multiple myeloma and some forms of leukemia. The total potential value of the deal, if all contingencies are met, is €628…